These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

884 related items for PubMed ID: 9880090

  • 1. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
    Nordberg A, Svensson AL.
    Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
    [Abstract] [Full Text] [Related]

  • 2. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
    Imbimbo BP.
    CNS Drugs; 2001 Dec; 15(5):375-90. PubMed ID: 11475943
    [Abstract] [Full Text] [Related]

  • 3. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW, Shirley KL, Small GW.
    Clin Pharmacokinet; 2002 Dec; 41(10):719-39. PubMed ID: 12162759
    [Abstract] [Full Text] [Related]

  • 4. Cholinesterase inhibitors for Alzheimer's disease.
    Birks J.
    Cochrane Database Syst Rev; 2006 Jan 25; 2006(1):CD005593. PubMed ID: 16437532
    [Abstract] [Full Text] [Related]

  • 5. Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.
    Wilkinson DG, Francis PT, Schwam E, Payne-Parrish J.
    Drugs Aging; 2004 Jan 25; 21(7):453-78. PubMed ID: 15132713
    [Abstract] [Full Text] [Related]

  • 6. Rivastigmine for Alzheimer's disease.
    Birks J, Grimley Evans J, Iakovidou V, Tsolaki M, Holt FE.
    Cochrane Database Syst Rev; 2009 Apr 15; (2):CD001191. PubMed ID: 19370562
    [Abstract] [Full Text] [Related]

  • 7. Cholinesterase Inhibitors for Alzheimer's Disease: Multitargeting Strategy Based on Anti-Alzheimer's Drugs Repositioning.
    Kabir MT, Uddin MS, Begum MM, Thangapandiyan S, Rahman MS, Aleya L, Mathew B, Ahmed M, Barreto GE, Ashraf GM.
    Curr Pharm Des; 2019 Apr 15; 25(33):3519-3535. PubMed ID: 31593530
    [Abstract] [Full Text] [Related]

  • 8. Pharmacodynamic, pharmacokinetic and pharmacogenetic aspects of drugs used in the treatment of Alzheimer's disease.
    Noetzli M, Eap CB.
    Clin Pharmacokinet; 2013 Apr 15; 52(4):225-41. PubMed ID: 23408070
    [Abstract] [Full Text] [Related]

  • 9. BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.
    Chianella C, Gragnaniello D, Maisano Delser P, Visentini MF, Sette E, Tola MR, Barbujani G, Fuselli S.
    Eur J Clin Pharmacol; 2011 Nov 15; 67(11):1147-57. PubMed ID: 21630031
    [Abstract] [Full Text] [Related]

  • 10. The tolerability and safety of cholinesterase inhibitors in the treatment of dementia.
    Inglis F.
    Int J Clin Pract Suppl; 2002 Jun 15; (127):45-63. PubMed ID: 12139367
    [Abstract] [Full Text] [Related]

  • 11. Pharmacodynamics of cholinesterase inhibitors suggests add-on therapy with a low-dose carbamylating inhibitor in patients on long-term treatment with rapidly reversible inhibitors.
    Darreh-Shori T, Hosseini SM, Nordberg A.
    J Alzheimers Dis; 2014 Jun 15; 39(2):423-40. PubMed ID: 24217282
    [Abstract] [Full Text] [Related]

  • 12. Potencies and selectivities of inhibitors of acetylcholinesterase and its molecular forms in normal and Alzheimer's disease brain.
    Rakonczay Z.
    Acta Biol Hung; 2003 Jun 15; 54(2):183-9. PubMed ID: 14535624
    [Abstract] [Full Text] [Related]

  • 13. Alzheimer's disease: beware of interactions with cholinesterase inhibitors.
    Prescrire Int; 2006 Jun 15; 15(83):103-6. PubMed ID: 16764099
    [Abstract] [Full Text] [Related]

  • 14. Rivastigmine for Alzheimer's disease.
    Birks J, Grimley Evans J, Iakovidou V, Tsolaki M.
    Cochrane Database Syst Rev; 2000 Jun 15; (4):CD001191. PubMed ID: 11034705
    [Abstract] [Full Text] [Related]

  • 15. Understanding and managing behavioural symptoms in Alzheimer's disease and related dementias: focus on rivastigmine.
    Robert P.
    Curr Med Res Opin; 2002 Jun 15; 18(3):156-71. PubMed ID: 12094826
    [Abstract] [Full Text] [Related]

  • 16. The pharmacology of donepezil: a new treatment of Alzheimer's disease.
    Wilkinson DG.
    Expert Opin Pharmacother; 1999 Nov 15; 1(1):121-35. PubMed ID: 11249555
    [Abstract] [Full Text] [Related]

  • 17. Galantamine: new preparation. The fourth cholinesterase inhibitor for Alzheimer's disease.
    Prescrire Int; 2001 Dec 15; 10(56):180-1. PubMed ID: 11824442
    [Abstract] [Full Text] [Related]

  • 18. Pharmacology and clinical efficacy of cholinesterase inhibitors.
    Jann MW.
    Am J Health Syst Pharm; 1998 Nov 01; 55 Suppl 2():S22-5. PubMed ID: 9809108
    [Abstract] [Full Text] [Related]

  • 19. Comparison of cholinesterase inhibitor utilization patterns and associated health care costs in Alzheimer's disease.
    Mucha L, Shaohung S, Cuffel B, McRae T, Mark TL, Del Valle M.
    J Manag Care Pharm; 2008 Jun 01; 14(5):451-61. PubMed ID: 18597574
    [Abstract] [Full Text] [Related]

  • 20. Donepezil: an anticholinesterase inhibitor for Alzheimer's disease.
    Shintani EY, Uchida KM.
    Am J Health Syst Pharm; 1997 Dec 15; 54(24):2805-10. PubMed ID: 9428950
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 45.